16.86
前日終値:
$15.97
開ける:
$15.76
24時間の取引高:
208.88K
Relative Volume:
1.77
時価総額:
$147.60M
収益:
$123.24M
当期純損益:
$136.00K
株価収益率:
-843.00
EPS:
-0.02
ネットキャッシュフロー:
$-148.99M
1週間 パフォーマンス:
+10.27%
1か月 パフォーマンス:
+13.54%
6か月 パフォーマンス:
+1.24%
1年 パフォーマンス:
-6.65%
Seres Therapeutics Inc Stock (MCRB) Company Profile
名前
Seres Therapeutics Inc
セクター
電話
617 945 9626
住所
200 SIDNEY STREET, CAMBRIDGE, MA
MCRB を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
MCRB
Seres Therapeutics Inc
|
16.86 | 139.81M | 123.24M | 136.00K | -148.99M | -0.02 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
390.30 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
565.97 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
442.73 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
652.43 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
309.69 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-05-08 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
2024-10-24 | ダウングレード | JP Morgan | Neutral → Underweight |
2023-06-26 | 再開されました | Oppenheimer | Outperform |
2023-04-21 | 開始されました | JP Morgan | Neutral |
2021-07-23 | ダウングレード | Goldman | Neutral → Sell |
2021-05-18 | 再開されました | Goldman | Neutral |
2021-03-05 | アップグレード | Chardan Capital Markets | Neutral → Buy |
2020-09-18 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
2020-08-18 | 開始されました | Piper Sandler | Overweight |
2020-08-11 | 繰り返されました | H.C. Wainwright | Buy |
2020-08-11 | アップグレード | Jefferies | Hold → Buy |
2019-04-30 | 開始されました | Jefferies | Hold |
2018-10-22 | 開始されました | Chardan Capital Markets | Buy |
2017-10-13 | 開始されました | Oppenheimer | Outperform |
2017-08-04 | 繰り返されました | H.C. Wainwright | Buy |
2017-02-01 | 繰り返されました | FBR & Co. | Outperform |
2016-08-12 | 繰り返されました | FBR Capital | Outperform |
2016-08-01 | ダウングレード | BofA/Merrill | Buy → Neutral |
2016-08-01 | 繰り返されました | H.C. Wainwright | Buy |
2016-07-29 | 再開されました | H.C. Wainwright | Buy |
2016-03-30 | 開始されました | FBR Capital | Outperform |
2016-03-03 | 開始されました | Guggenheim | Buy |
2016-01-25 | 開始されました | H.C. Wainwright | Buy |
2015-10-22 | アップグレード | BofA/Merrill | Neutral → Buy |
2015-07-22 | 開始されました | Canaccord Genuity | Buy |
2015-07-21 | 開始されました | Goldman | Neutral |
2015-07-21 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Seres Therapeutics Inc (MCRB) 最新ニュース
Seres Therapeutics Inc. Bounces Off Moving Average SupportReal Trader Watchlist of Hot Stocks Released - metal.it
Seres (MCRB) Q2 Loss Narrows 34% - AOL.com
Seres Therapeutics Reports Q2 2025 Financial Results - The Globe and Mail
Seres Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks
Seres Therapeutics shares fall 1.90% after-hours following Q2 2025 earnings call. - AInvest
Promising Developments and Strategic Partnerships Drive Buy Rating for Seres Therapeutics - TipRanks
Seres Therapeutics outlines global Phase II SER-155 trial with 248-patient enrollment amid partnership talks - MSN
Seres Therapeutics: Q2 Earnings Snapshot - Connecticut Post
Seres Therapeutics: Unpacking Strategic Contradictions in Partnerships and FDA Engagements - AInvest
Seres Therapeutics, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:MCRB) - Seeking Alpha
Transcript : Seres Therapeutics, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Sana Biotechnology shares fall 14.12% after-hours following Seres Therapeutics' board changes and clinical advancement updates. - AInvest
Seres Therapeutics, Inc. SEC 10-Q Report - TradingView
Earnings call transcript: Seres Therapeutics reports larger-than-expected Q2 loss - Investing.com Canada
Seres Therapeutics quarterly loss per share $2.27 - MarketScreener
Seres Therapeutics August 2025 slides: SER-155 shows 77% infection reduction - Investing.com
Nxera debuts an obesity pipeline; BridgeBio battles Alynam for market share - Yahoo Finance
Seres Therapeutics: A High-Conviction Biotech Buy Amid Clinical and Strategic Momentum - AInvest
Seres Therapeutics Reports Second Quarter 2025 Financial Results - GuruFocus
Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates - Yahoo Finance
Seres Therapeutics Inc. Stock Analysis and ForecastAchieve consistent profits with proven methods - Jammu Links News
Is Seres Therapeutics Inc. a growth stock or a value stockRapid portfolio appreciation - Jammu Links News
Is Seres Therapeutics Inc. a good long term investmentAchieve breakthrough gains with smart trades - Jammu Links News
How does Seres Therapeutics Inc. compare to its industry peersMaximize your portfolio’s growth potential - Jammu Links News
What are Seres Therapeutics Inc. company’s key revenue driversConsistent high-yield stocks - Jammu Links News
When is Seres Therapeutics Inc. stock expected to show significant growthInvest confidently with real-time data - Jammu Links News
What are analysts’ price targets for Seres Therapeutics Inc. in the next 12 monthsBuild a diversified portfolio for maximum returns - Jammu Links News
Should I hold or sell Seres Therapeutics Inc. stock in 2025Build a portfolio that grows with the market - Jammu Links News
What analysts say about Seres Therapeutics Inc. stockUnmatched profit potential - Jammu Links News
What makes Seres Therapeutics Inc. stock price move sharplyBuild wealth with steady, reliable stocks - Jammu Links News
Why is Seres Therapeutics Inc. stock attracting strong analyst attentionRetirement Planning Entry Points For Consistent Profits - Jammu Links News
Is Seres Therapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis Inside - metal.it
Seres Therapeutics: Speculative Gem with FDA Breakthrough Potential - AInvest
Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthrough - Seeking Alpha
Why Seres Therapeutics Inc. stock attracts strong analyst attentionEntry Zone Strategy for Consistent Profit Shared - metal.it
What institutional investors are buying Seres Therapeutics Inc. stockPhenomenal wealth increase - Jammu Links News
How many analysts rate Seres Therapeutics Inc. as a “Buy”Build wealth with reliable stock picks - Jammu Links News
Will Seres Therapeutics Inc. Recover After Recent DeclineStock Market Entry Timing Signals Revealed - metal.it
What is the dividend policy of Seres Therapeutics Inc. stockSkyrocketing returns - Jammu Links News
Seres Therapeutics Inc (MCRB) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):